

CLAIMS

1. The crystalline form of the compound 3-isopropyl-6-[4-(2,5-difluoro-phenyl)-oxazol-5-yl]-[1,2,4]triazolo[4,3-a]pyridine having the single crystal x-ray crystallographic data.

	Form A
Empirical formula	C ₁₈ H ₁₄ N ₄ OF ₂
Formula weight	340.33
Temperature (K)	268 (2)
Crystal size (mm)	0.04 x 0.06 x 0.15
Space group	P2 ₁ /n monoclinic
Unit cell dimensions	a = 6.6546 (11) Å b = 25.675 (4) Å c = 10.5455 (17) Å α = 90° β = 98.918 (5)° γ = 90°
Z (per formula)	4
Density (g/cm ³)	1.270
R	0.0783

5

2. The crystalline form of the compound 3-isopropyl-6-[4-(2,5-difluoro-phenyl)-oxazol-5-yl]-[1,2,4]triazolo[4,3-a]pyridine having the single crystal x-ray crystallographic data.

	Form B
Empirical formula	C ₁₈ H ₁₄ N ₄ OF ₂
Formula weight	340.33
Temperature (K)	298 (2)
Crystal size (mm)	0.10 x 0.20 x 0.24
Space group	P2 ₁ /c monoclinic
Unit cell dimensions	a = 20.7164 (6) Å b = 10.7621 (3) Å c = 14.3522 (4) Å α = 90° β = 92.1490 (10)° γ = 90°
Z (per formula)	8

Density (g/cm ³)	1.414
R	0.0450

3. The crystalline form of the compound 3-isopropyl-6-[4-(2,5-difluoro-phenyl)-oxazol-5-yl]-[1,2,4]triazolo[4,3-a]pyridine having the single crystal x-ray crystallographic data.

Form D	
Empirical formula	C ₁₈ H ₁₄ N ₄ OF ₂ ·3H ₂ O
Formula weight	394.38
Temperature (K)	298 (2)
Crystal size (mm)	0.40 x 0.28 x 0.10
Space group	P2 ₁ /n monoclinic
Unit cell dimensions	a = 15.1326 (17) Å b = 6.9630 (8) Å c = 19.229 (2) Å α = 90° β = 108.087 (2)° γ = 90°
Z (per formula)	4
Density (g/cm ³)	1.360
R	0.0471

5

4. The crystalline form of the compound 3-isopropyl-6-[4-(2,5-difluoro-phenyl)-oxazol-5-yl]-[1,2,4]triazolo[4,3-a]pyridine having powder x-ray diffraction peaks at angle 2-theta of 9.1, 13.8, 17.4 and 22.6 degrees.

10 5. The crystalline form of the compound 3-isopropyl-6-[4-(2,5-difluoro-phenyl)-oxazol-5-yl]-[1,2,4]triazolo[4,3-a]pyridine having powder x-ray diffraction peaks at angle 2-theta of 8.5, 11.2, 14.8, 16.9, 17.1, 19.7, 22.3, 26.0 and 27.9 degrees.

6. The crystalline form of the compound 3-isopropyl-6-[4-(2,5-difluoro-phenyl)-oxazol-5-yl]-[1,2,4]triazolo[4,3-a]pyridine having powder x-ray diffraction peaks at angle 2-theta of 7.4, 12.8, 14.8, 19.6, 22.3, 25.7 and 26.8 degrees.

15 7. The crystalline form of the compound 3-isopropyl-6-[4-(2,5-difluoro-phenyl)-oxazol-5-yl]-[1,2,4]triazolo[4,3-a]pyridine having powder x-ray diffraction peaks at angle 2-theta of 6.6, 13.8, 16.0, 17.3, 17.6, 22.5, 25.6 and 26.4 degrees.

8. The crystalline form of the compound 3-isopropyl-6-[4-(2,5-difluoro-phenyl)-oxazol-5-yl]-[1,2,4]triazolo[4,3-a]pyridine having powder x-ray diffraction peaks at angle 2-theta of 7.7, 8.4, 15.5, 17.2, 23.0, 26.7 and 28.6 degrees.

9. The crystalline form of the compound 3-isopropyl-6-[4-(2,5-difluoro-phenyl)-oxazol-5-yl]-[1,2,4]triazolo[4,3-a]pyridine having thermal events between 105-125°C, 148°C and 173°C.

10. The crystalline form of the compound 3-isopropyl-6-[4-(2,5-difluoro-phenyl)-oxazol-5-yl]-[1,2,4]triazolo[4,3-a]pyridine having a melting endotherm at 172-175°C.

11. The crystalline form of the compound 3-isopropyl-6-[4-(2,5-difluoro-phenyl)-oxazol-5-yl]-[1,2,4]triazolo[4,3-a]pyridine having two thermal events at between 150-165 and 172-175°C.

12. The crystalline form of the compound 3-isopropyl-6-[4-(2,5-difluoro-phenyl)-oxazol-5-yl]-[1,2,4]triazolo[4,3-a]pyridine having a broad endothermic event between 30-120°C and a melting endotherm at 177°C.

13. The crystalline form of the compound 3-isopropyl-6-[4-(2,5-difluoro-phenyl)-oxazol-5-yl]-[1,2,4]triazolo[4,3-a]pyridine having an endotherm/exothermic event at between 70-120°C and a melting endotherm at 175-177°C.

14. The crystalline form of the compound 3-isopropyl-6-[4-(2,5-difluoro-phenyl)-oxazol-5-yl]-[1,2,4]triazolo[4,3-a]pyridine having a ¹³C ss-NMR chemical shifts of 159.2, 157.2, 156.0, 154.9, 153.0, 150.2, 144.4, 142.4, 129.2, 125.3, 123.7, 121.9, 112.0, 118.3, 116.4, 114.9, 24.8, 20.8, 18.7, and 17.0 ppm.

15. The crystalline form of the compound 3-isopropyl-6-[4-(2,5-difluoro-phenyl)-oxazol-5-yl]-[1,2,4]triazolo[4,3-a]pyridine according to claim 10, having a ¹³C ss-NMR chemical shifts of 159.2, 157.2, 156.0, 154.9, 153.0, 150.2, 144.4, 142.4, 129.2, 125.3, 123.7, 121.9, 112.0, 118.3, 116.4, 114.9, 24.8, 20.8, 18.7, and 17.0 ppm.

16. The crystalline form of the compound 3-isopropyl-6-[4-(2,5-difluoro-phenyl)-oxazol-5-yl]-[1,2,4]triazolo[4,3-a]pyridine according to claim 5, having a ¹³C ss-NMR chemical shifts of 159.2, 157.2, 156.0, 154.9, 153.0, 150.2, 144.4, 142.4, 129.2, 125.3, 123.7, 121.9, 112.0, 118.3, 116.4, 114.9, 24.8, 20.8, 18.7, and 17.0 and a melting endotherm at 173-175°C.

17. The crystalline form of the compound 3-isopropyl-6-[4-(2,5-difluoro-phenyl)-oxazol-5-yl]-[1,2,4]triazolo[4,3-a]pyridine according to claim 2, having a ¹³C ss-NMR chemical shifts of 159.2, 157.2, 156.0, 154.9, 153.0, 150.2, 144.4, 142.4, 129.2, 125.3, 123.7, 121.9, 112.0, 118.3, 116.4, 114.9, 24.8, 20.8, 18.7, and 17.0 and a Differential Scanning Calorimetry melting endotherm at 173-175°C and powder x-ray diffraction peaks at angle 2-theta of 8.5, 11.2, 14.8, 16.9, 19.7, 22.3, 26.0 and 27.9 degrees.

18. The crystalline form of the compound 3-isopropyl-6-[4-(2,5-difluoro-phenyl)-oxazol-5-yl]-[1,2,4]triazolo[4,3-a]pyridine according to claim 4, having thermal events between 105-125°C, 148°C and 173°C.

5 19. The crystalline form of the compound 3-isopropyl-6-[4-(2,5-difluoro-phenyl)-oxazol-5-yl]-[1,2,4]triazolo[4,3-a]pyridine according to claim 1, having powder x-ray defraction peaks at angle 2-theta of 9.1, 13.8, 17.4 and 22.6 and thermal events between 105-125°C, 148°C and 173°C.

10 20. The crystalline form of the compound 3-isopropyl-6-[4-(2,5-difluoro-phenyl)-oxazol-5-yl]-[1,2,4]triazolo[4,3-a]pyridine according to claim 7, having a broad endothermic event between 30-120°C and a melting endotherm at 172-175°C.

21. The crystalline form of the compound 3-isopropyl-6-[4-(2,5-difluoro-phenyl)-oxazol-5-yl]-[1,2,4]triazolo[4,3-a]pyridine according to claim 3, having powder x-ray defraction peaks at angle 2-theta of 6.6, 13.8, 16.0, 17.3, 17.6, 22.5, 25.6 and 26.4 and a broad endothermic event between 30-120°C and a melting endotherm at 177°C.

15 22. The crystalline form of the compound 3-isopropyl-6-[4-(2,5-difluoro-phenyl)-oxazol-5-yl]-[1,2,4]triazolo[4,3-a]pyridine according to claim 8, having an endotherm/exothermic event at between 70-120°C and a melting endotherm at 175-177°C.